Not available
Quote | ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC)
Last: | $0.17645 |
---|---|
Change Percent: | -31.93% |
Open: | $0.1979 |
Close: | $0.17645 |
High: | $0.1979 |
Low: | $0.17645 |
Volume: | 297 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
News | ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC)
EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613 PR Newswire MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug...
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil PR Newswire Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , ...
Message Board Posts | ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC)
Subject | By | Source | When |
---|---|---|---|
They have no say. This I know for fact. | Benwahsauce | investorshub | 04/12/2023 1:26:34 AM |
Thanks for the tip Veteran. Haha. Anyways hope | OTC_Hussler | investorshub | 04/12/2023 12:48:41 AM |
Mad? Too old for that Never show your hand on | Benwahsauce | investorshub | 04/11/2023 11:48:37 PM |
Haha. How many you got? I showed mine | OTC_Hussler | investorshub | 04/11/2023 9:36:25 PM |
Call TD and speak with them. They are | OTC_Hussler | investorshub | 04/11/2023 9:35:36 PM |
News, Short Squeeze, Breakout and More Instantly...
ImmunoCellular Therapeutics Ltd. Company Name:
IMUC Stock Symbol:
OTCMKTS Market:
EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613 PR Newswire MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug...
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil PR Newswire Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , ...
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology indu...